P Swetha¹, J Sumalatha^2* and S Nelson Kumar³

¹Department of Pharmaceutical Analysis, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, – 516003, India
²Department of Pharmaceutical Chemistry, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, – 516003, India
³Department of Pharmacology, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, – 516003, India

*Corresponding Author: J Sumalatha, Department of Pharmaceutical Chemistry, P. Rami Reddy Memorial College of Pharmacy, Kadapa, Andhra Pradesh, – 516003, India.

Received: April 30, 2026; Published: May 26, 2026

Abstract

A new RP-HPLC method was established for the concurrent measurement of Solifenacin and Silodosin in pharmaceutical products, characterized by its speed, precision, and sensitivity. To achieve effective separation, the researchers utilized a Waters Alliance e2695 system paired with a Hyperclone C18 column (250 × 4.6 mm, 5 μm). The process involved a mobile phase composed of acetonitrile and 0.1% formic acid (50:50 v/v), which was delivered at a constant flow rate of 1.0 mL/min. Analysis was performed at ambient temperature, with detection set at a wavelength of 272 nm using a PDA detector. The integrity of the system was confirmed through suitability parameters, which recorded theoretical plates exceeding 2000 and a tailing factor under 2.0 for both active ingredients. Additionally, the %RSD remained below 2.0, showcasing the method’s high level of reproducibility and precision. This analytical approach was fully validated according to ICH guidelines, proving to be a robust, accurate, and budget-friendly option. Because it operates without interference from pharmaceutical excipients, it is highly recommended for routine laboratory analysis and stability testing of Solifenacin and Silodosin.

Keywords: RP-HPLC; Solifenacin and Silodosin; Method Validation; Stability Studies

References

1. Chapple Christopher R., et al. “Randomized Double-Blind Active-Controlled Phase 3 Study to Assess the Efficacy and Safety of Silodosin in Patients with Signs and Symptoms of Benign Prostatic Hyperplasia”. European Urology3 (2011): 342-352.
2. Andersson KE and M Yoshida. “Antimuscarinics and the Overactive Detrusor—Which Is the Main Mechanism of Action?” European Urology1 (2003): 1-5.
3. Kumar D A., et al. “Development and Validation of RP-HPLC Method for Estimation of Solifenacin Succinate in Tablet Dosage Form”. International Journal of Pharmaceutical Sciences and Research4 (2017): 1568-1573.
4. Raj K Sai Krupa., et al. "Method Development and Validation of Solifenacin Succinate in Pharmaceutical Dosage Form Using First Order Derivative UV Spectrophotometry”. Annals of Phytomedicine1 (2022): S79-S82.
5. Desai Nilesh., et al. "Development & Validation of Stability Indicating HPLC Method for Determination of Solifenacin in Bulk Formulations”. International Journal of Pharmacy and Pharmaceutical Sciences1 (2011): 70-74.
6. Spandana KVLD and NJP Subhashini. "Analytical Method Development and Validation for the Simultaneous Estimation of Mirabegron and Solifenacin in Bulk and Pharmaceutical Dosage Form by RP-HPLC”. Indo American Journal of Pharmaceutical Sciences6 (2022): 549-558.
7. Tanuja A., et al. "Stability Indicating RP-HPLC Method Development and Validation for the Determination of Solifenacin Succinate in Bulk and its Pharmaceutical Formulation”. Research Journal of Pharmacy and Technology7 (2021): 3509-3514.
8. Sahana R., et al. "Analytical Method Development and Validation of Solifenacin Succinate by Using UV-Spectrophotometric Method”. International Journal of Novel Research and Development10 (2024): 9-13.
9. Arif M Mohammed, et al. "Second Derivative UV Spectrophotometric Quantification of Solifenacin Succinate in Pharmaceuticals Employing Multivariate Calibration Technique: Assessment of Greenness Profile”. International Journal of Biology, Pharmacy and Allied Sciences 8 (2023): 3604-3616.
10. Kadam Manoj M., et al. "Development and Validation of Stability Indicating UHPLC Method for the Quantitative Estimation of Mirabegron and Solifenacin Succinate in Pharmaceutical Dosage Form”. Journal of Pharmaceutical Negative Results7 (2022): 6727-6737.
11. Damle MC and PC Rokade. "Development and Validation of Stability-Indicating HPTLC Method for Determination of Solifenacin Succinate as bulk Drug and in Tablet Dosage Form”. International Journal of Pharmaceutical Sciences and Drug Research 4 (2016): 218-222.
12. Xifra Raúl., et al. "Facile Access to Solifenacin Impurity K: One-Step Synthesis and an HPLC-MS Method for Its Determination”. Molecules 13 (2024): 3011.
13. Maheshwari Dilip., et al. "Spectrophotometric and HPLC-MS/MS for Determination of Silodosin in Pharmaceutical Formulation”. Austin Journal of Analytical and Pharmaceutical Chemistry2 (2024): 1-5.
14. Ushasree G and Kondreddy Vinod Kumar. "Quality by Design (QbD) Based Development and Validation of RP-HPLC Method for Quantification of Silodosin and Mirabegron in Pharmaceutical Dosage Forms”. International Journal of Advanced Science and Engineering3 (2026): 6421-6432.
15. Shaik Jafer Vali., et al. “Development of Stability-Indicating UHPLC Method for the Quantitative Determination of Silodosin and Its Related Substances”. Journal of Chromatographic Science (2013): 1-8.
16. Patnaik Soumya Stuti., et al. "Stability Indicating UV-Spectroscopic Method Development and Validation of Silodosin in Bulk and Capsule Dosage Form—A Green Analytical Approach”. European Chemical Bulletin10 (2023): 10261-10269.
17. Lakshmi KS and CVN Prasad. “Analytical Methods for Simultaneous Estimation of Combined Drug Products by RP-HPLC: A Review”. Journal of Pharmaceutical Analysis6 (2019): 371-381.
18. Patel D B and N J Patel. “Validated RP-HPLC Method for Determination of Silodosin in Pharmaceutical Dosage Form”. Asian Journal of Pharmaceutical and Clinical Research 2 (2016): 210-214.
19. Reddy Ranjith., et al. “Development and Validation of a Stability Indicating Analytical Method for Determination of Related Substances by RP-HPLC for Solifenacin Succinate in Solifenacin Succinate Tablets”. Pharmacophore2 (2017): 11-23.
20. Lodha S., et al. “High-Performance Thin Layer Chromatographic Method Development and Validation for Simultaneous Estimation of Solifenacin Succinate and Silodosin Using Quality by Design Approach and Greenness Assessment”. Separation Science Plus (2023).
21. Dhiman S., et al. “Analytical Reversed-Phase High-Performance Liquid Chromatography Method Development for Silodosin and Solifenacin in Bulk and Marketed Formulation Using Analytical Quality by Design Approach”. Separation Science Plus (2022).
22. Wadie Mina., et al. “A Green and Versatile HPLC-DAD Method for Determination of Silodosin and Solifenacin in Their Newly Combined Formulation: Evaluation of Content Uniformity and Dissolution Profiles”. Journal of Pharmaceutical Analysis (2025).

Citation

Citation: J Sumalatha. et al. “A Stability Indicating RP-HPLC Method for Simultaneous Estimation of Solifenacin and Silodosin in Bulk and Formulation". Acta Scientific Pharmaceutical Sciences 10.5 (2026): 47-59.

Copyright

Copyright: © 2026 J Sumalatha. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.